MDxHealth sees FY23 revenue $65M-$70M, consensus $67.03M

"Further, we are also pleased to note the expanded indication for our GPS test in the recently updated NCCN Prostate Cancer guidelines", continued McGarrity. "The addition of GPS to our current menu of tests targeted into urology and prostate cancer reflects our strategy to generate sustainable growth and enable mdxhealth to become the leading precision diagnostics company with the most comprehensive test menu focused on prostate cancer. While early, we are well into our integration plan for our GPS test and have our expanded field sales organization in place to support continued growth. With multiple levers for sustainable revenue growth, the company is initiating 2023 revenue guidance of $65-70 million."